How do I buy shares of Numinus Wellness? Shares of LKYSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Full Answer
Can the numinus wellness stock price rise to $10?
But the fundamentals underlying Numinus Wellness are very compelling, and if a few things go right for this company, the LKYSF stock price could soar to $10 or more over the next few years. Why? Because of the Shroom Boom.
What is numinus health?
The Numinus Health segment operates the wellness centre where professional therapists and health professionals use supportive therapies and technologies to focus on treating mental health and substance abuse. The company was founded by Payton Nyquvest and Stacey Wallin in 2018 and is headquartered in Vancouver, Canada.
Can numinus wellness sustain its leadership in the Shroom Boom?
With that cash balance and its recent business momentum, Numinus Wellness has what it takes to sustain its early leadership in the Shroom Boom via acquisitions, R&D investment, and strategic partnerships. Long term, we see Numinus emerging as one of the more important players in the psychedelic-inspired medicines space.
Is numinus (lkysf) a penny stock to buy?
Numinus is worth less than $200 million — and $65 million of that market cap is covered cash. Clearly, LKYSF stock has huge upside potential. So, if there were every a time and a place to buy a penny stock, that time is now and the stock is Numinus. Here’s a deeper look. When it comes to LKYSF stock, it’s all about the Shroom Boom.
Who are Numinus Wellness' key executives?
Numinus Wellness' management team includes the following people: Payton Nyquvest , Chairman, President & Chief Executive Officer Michael Tan , C...
Who are some of Numinus Wellness' key competitors?
Some companies that are related to Numinus Wellness include Awakn Life Sciences (AWKNF) , Eurofins Scientific (ERRFY) , Extendicare (EXETF) , M...
What is Numinus Wellness' stock symbol?
Numinus Wellness trades on the OTCMKTS under the ticker symbol "LKYSF."
How do I buy shares of Numinus Wellness?
Shares of LKYSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Numinus Wellness' stock price today?
One share of LKYSF stock can currently be purchased for approximately $0.29.
What is Numinus Wellness' official website?
The official website for Numinus Wellness is www.numinus.ca .
Where are Numinus Wellness' headquarters?
Numinus Wellness is headquartered at 33 Water Street, Vancouver, BC V6B .
How can I contact Numinus Wellness?
Numinus Wellness' mailing address is 33 Water Street, Vancouver, BC V6B . The company can be reached via phone at (833) 686-4687 .
Who are some of Numinus Wellness' key competitors?
Some companies that are related to Numinus Wellness include Awakn Life Sciences (AWKNF), Eurofins Scientific (ERRFY), Extendicare (EXETF), Medipharm Labs (MLCPF), Ping An Healthcare and Technology (PANHF), Siemens Healthineers (SEMHF), SQI Diagnostics (SQIDF), Vaneck Vectors Global Health Leaders Etf (HLTH) and Vigil Health Solutions (VIGLF). View all of LKYSF's competitors..
What is Numinus Wellness' stock symbol?
Numinus Wellness trades on the OTCMKTS under the ticker symbol "LKYSF."
How do I buy shares of Numinus Wellness?
Shares of LKYSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is Numinus Wellness' stock price today?
One share of LKYSF stock can currently be purchased for approximately $0.45.
Where are Numinus Wellness' headquarters?
Numinus Wellness is headquartered at 33 Water Street, Vancouver, BC V6B.
How can I contact Numinus Wellness?
Numinus Wellness' mailing address is 33 Water Street, Vancouver, BC V6B. The company can be reached via phone at (833) 686-4687.
What is Numinus Wellness?
is a health care company that operates a testing and research facility that can support the emerging market of psychedelic therapies to supplement existing options in addressing mental illness, addictions, and post-traumatic stress disorder. Through its subsidiary, it tests and analyzes cannabis products from licensed producers. It also allows to test, possess, buy, and sell MDMA, psilocybin, psilocin, DMT and mescaline. The company was founded by Payton Nyquvest and Stacey Wallin on June 26, 1962 and is headquartered in Vancouver, Canada.
Where is Numinus Health located?
The company was founded by Payton Nyquvest and Stacey Wallin in 2018 and is headquartered in Vancouver, Canada.
Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022
Numinus Wellness Inc.
Numinus Appoints New Bioscience Advisors to Advance IP Development
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the appointment of three key advisors to its new Bioscience Advisory Board.
Stocks in play: Numinus Wellness Inc
Announced that its research facility, Numinus Bioscience, has been included on Health Canada's list ...
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its research facility, Numinus Bioscience, has been included on Health Canada's list of federally licensed psilocybin producers.
Numinus Wellness Inc. Graduates to the OTCQX Best Market
Numinus Wellness Inc.
Numinus to Participate in Citi's Psychedelic Drug Call Series on February 2, 2022
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Citi's Psychedelic Drug Call Series to be hosted virtually on Wednesday, February 2, 2022.
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Curaleaf completed the $210 million acquisition of Bloom Dispensaries in Arizona. Canadian retail cannabis sales fell 3% from October in November, rising 36% from a year ago.
Where is Numinus Wellness located?
Numinus Wellness is a $180 million, fully-integrated and verticalized mental health company based in Canada that is focused on developing and delivering psychedelic-assisted psychotherapies to address various mental health and substance abuse disorders.
How much is Numinus worth?
Numinus is worth less than $200 million — and $65 million of that market cap is covered cash. Clearly, LKYSF stock has huge upside potential. So, if there were every a time and a place to buy a penny stock, that time is now and the stock is Numinus. Here’s a deeper look.
Is Numinus a psychedelic company?
Meanwhile, as the leading company in psychedelics-inspired therapies research and testing, Numinus is also the leading company when it comes to commercializing and delivering these drugs. Through its Health division, Numinus is already actively supporting three clinics in administering ketamine-assisted psychotherapy.
Is Numinus Wellness a leader in psychedelic medicine?
It’s one of the few companies in the world that is actively pushing forward of the psychedelic-inspired medicines front, and indeed, one could argue that Numinus has emerged as a leader in this field.
Highlights
Numinus (NUMI) is engaged in developing therapies through psychedelic substances.
Is Numinus Wellness (TSX:NUMI) a stock to buy?
Seeing the 52-week high of C$ 2.45 apiece, the stock of Numinus Wellness seems to be undervalued at its present price. Despite a downward trend, the Numinus stock has returned about 186 per cent in the last 12 months and has declined by 12 per cent since the past three months.
Bottom line
Numinus closed the quarter ending May 31 with a C$ 63.2 million cash position. In addition, the healthcare company generated revenues of C$ 562,076 in Q3 2021, representing an increase of 160 per cent year-over-year (YoY).
Signals & Forecast
There are few to no technical positive signals at the moment. The Numinus Wellness Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
Numinus Wellness Inc finds support from accumulated volume at $0.44 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Numinus Wellness Inc stock A Buy?
The Numinus Wellness Inc stock holds several negative signals and despite the positive trend, we believe Numinus Wellness Inc will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
